-
Plus Therapeutics Delivers Key Updates on REYOBIQ and CNSide Commercial Strategy
NASDAQ: $PSTV In a significant communication to investors and the medical community, Plus Therapeutics, Inc. has recently issued a comprehensive business update focusing on two critical aspects of its pipeline and commercial strategy: the clinical program for REYOBIQ (also known as the LOTUS trial) and the planned U.S. commercialization pathway for CNSide. Advancements in the…